Welcome to our dedicated page for Surgery Partners SEC filings (Ticker: SGRY), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Medicare rate updates, shifting payor mixes and physician joint-venture agreements turn every Surgery Partners disclosure into a maze of acronyms and footnotes. If you have ever searched through a 300-page document just to learn which facilities drove same-store growth, you know the challenge. Stock Titan brings clarity by pairing each release with AI-powered summaries that translate reimbursement tables and regulatory language into plain English.
You will find every filing here as soon as it hits EDGAR: the Surgery Partners annual report 10-K simplified for long-term trends, each Surgery Partners quarterly earnings report 10-Q filing broken down into case-volume and payor-mix drivers, and every Surgery Partners 8-K material events explained so you see why management moved quickly. Need trading intel? Our dashboard tracks Surgery Partners insider trading Form 4 transactions and delivers Surgery Partners Form 4 insider transactions real-time. For governance questions, the Surgery Partners proxy statement executive compensation section highlights how physician leaders are paid. All documents come with concise, AI-generated key points so you can start understanding Surgery Partners SEC documents with AI instead of parsing line items yourself.
Use these insights to compare segment margins across facilities, monitor Surgery Partners executive stock transactions Form 4 before earnings, and follow guidance revisions the moment they appear. Whether you are preparing a model, monitoring covenant compliance, or simply looking for Surgery Partners earnings report filing analysis, our platform saves hours and ensures nothing slips past you.
Surgery Partners' Chief Financial Officer, David T. Doherty, reported a sale of common stock on 08/08/2025. The Form 4 shows 47,491 shares sold at a weighted average price of $23.39, and lists 103,377 shares held following the transaction, all shown as direct ownership.
The filing includes an explanatory note that the reported price is a weighted average and identifies Jennifer Baldock as the attorney-in-fact who signed the form on 08/08/2025. The reporting person’s address is shown as Surgery Partners' Brentwood, TN office and the form indicates the filer is an officer serving as Chief Financial Officer.
Form 144 summary for Surgery Partners, Inc. (SGRY)
This Form 144 notifies a proposed sale of 47,491 shares of common stock via UBS Financial Services Inc. on 08/08/2025 on NASDAQ. The filing reports an aggregate market value of $1,110,769 and lists total shares outstanding as 128,209,410. All listed shares were acquired via equity vesting from Surgery Partners on dated entries between 08/28/2022 and 03/02/2025. The table of vesting entries sums to the 47,491 shares to be sold. The filing indicates no securities sold in the past three months ("Nothing to Report").
Surgery Partners, Inc. (Nasdaq: SGRY) filed a Form 8-K dated 5 Aug 2025. Under Item 2.02, the Company states it has furnished—not filed—a press release (Exhibit 99.1) that outlines results for the three- and six-month periods ended 30 Jun 2025. No numerical performance data are included in the 8-K itself. The filing notes that any non-GAAP measures discussed in the release are reconciled to the most comparable GAAP figures within that exhibit. Pursuant to General Instruction B.2, the furnished information is not subject to Section 18 liability and is not incorporated by reference into other SEC filings. Exhibit 104 provides the Inline XBRL cover page tag set.
Schedule 13G/A (Amendment No. 2) � Surgery Partners, Inc. (SGRY)
Janus Henderson Group plc ("JHG") filed an amended Schedule 13G on 06/30/2025 reporting its beneficial ownership of Surgery Partners common stock. The filing, signed 07/07/2025, shows JHG and its investment-adviser subsidiaries collectively hold 12,954,916 shares, representing 10.1 % of the outstanding class. All voting and dispositive authority over these shares is reported as shared; JHG claims no sole power.
The Janus Henderson Contrarian Fund, a Massachusetts-organized investment vehicle within the JHG complex, is listed separately with 11,678,754 shares, or 9.1 % of the class, also entirely under shared voting and dispositive power.
- Reporting persons: Janus Henderson Group plc; Janus Henderson Contrarian Fund
- Total beneficial ownership (JHG): 12.95 million shares
- Ownership percentage: 10.1 %
- Event date: 06/30/2025
- Certification: Shares acquired & held in the ordinary course; no intent to influence control
Crossing the 10 % threshold makes JHG one of SGRY’s largest passive institutional shareholders and subjects it to ongoing reporting under Section 13(d). The filing contains no indication of activist intentions or transactions beyond the reported holdings.
FAQ
What is the current stock price of Surgery Partners (SGRY)?
What is the market cap of Surgery Partners (SGRY)?
